Background Pancreatic ductal adenocarcinoma (PDAC) is largely refractory to immune checkpoint blockade, owing to its ...
PRKAG2 syndrome is an autosomal dominant Atrium Therapeutics has received clearance from the US Food and Drug Administration ...
Eleven new molecular drug targets receive approval in 2025, expanding treatment options for rare diseases, cancer, and infectious diseases.
Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the U.S. Food and Drug Administration ...
Acrivon Therapeutics trades below cash value, with the market deeply discounting its platform and pipeline despite promising ...
Morning Overview on MSN
Scientists found a hidden gatekeeper inside brain cells that could help fight Alzheimer’s
A lattice-like scaffold hidden inside neurons acts as a spatial gatekeeper for how brain cells absorb material from their ...
The FDA just approved a new drug for use in ER+/HER2- metastatic breast cancer, based on a large study led by Fred Hutch's Dr ...
US FDA clears Atrium Therapeutics’ IND application for ATR 1072 to treat of PRKAG2 syndrome: San Diego Wednesday, July 15, 2026, 13:00 Hrs [IST] Atrium Therapeutics, Inc., a bio ...
Researchers ranked 83 preclinical candidates for preventing or treating preeclampsia and eclampsia, identifying 11 as having ...
Halia Therapeutics today announced two posters at the Alzheimer's Association International Conference (AAIC) 2026, July ...
Researchers ranked 11 preeclampsia therapy candidates as high-potential, but evidence gaps, safety concerns and limited ...
Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results